Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass

European Journal of Cardio-thoracic Surgery

Volumn 34, Issue 3, 2008, Pages 653-660

  Banz, Yara ^a,b   Rieben, Robert ^a,b   Zobrist, Claudia ^c   Meier, Pascal ^b   Shaw, Sidney ^a   Lanz, Jonas ^a   Carrel, Thierry ^b   Berdat, Pascal ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Complement inhibition; Cytoprotection; Endothelium; Ischemia; Reperfusion

Indexed keywords

CREATINE KINASE MB; DEXTRAN SULFATE; ENDOTHELIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHATE BUFFERED SALINE; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CLAMPING; ARTICLE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; ELECTROCARDIOGRAPHY MONITORING; ENZYME BLOOD LEVEL; EXTRACORPOREAL CIRCULATION; HEART ARREST; HEART FUNCTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RIGHT VENTRICLE PRESSURE; INVASIVE PROCEDURE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG FLUID; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REPERFUSION INJURY; SWINE; TISSUE SECTION; TREATMENT OUTCOME; WATER CONTENT; WEANING;

ANIMALS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOTHELIN-1; HEART ARREST, INDUCED; HEMODYNAMICS; INFLAMMATION MEDIATORS; LUNG DISEASES; MYOCARDIAL REPERFUSION INJURY; PULMONARY EDEMA; REPERFUSION INJURY; SUS SCROFA;

EID: 49149124344     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.05.024     Document Type: Article

References (25)

1. Elgebaly S.A., Houser S.L., el Kerm A.F., Doyle K., Gillies C., and Dalecki K. Evidence of cardiac inflammation after open heart operations. Ann Thorac Surg 57 (1994) 391-396
2. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., Wildevuur C.R., Eijsman L., Trouwborst A., and Hack C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
3. Fitch J.C., Rollins S., Matis L., Alford B., Aranki S., Collard C.D., Dewar M., Elefteriades J., Hines R., Kopf G., Kraker P., Li L., O'Hara R., Rinder C., Rinder H., Shaw R., Smith B., Stahl G., and Shernan S.K. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100 (1999) 2499-2506
4. Berdat P.A., Eichenberger E., Ebell J., Pfammatter J.P., Pavlovic M., Zobrist C., Gygax E., Nydegger U., and Carrel T. Elimination of proinflammatory cytokines in pediatric cardiac surgery: analysis of ultrafiltration method and filter type. J Thorac Cardiovasc Surg 127 (2004) 1688-1696
5. Mulivor A.W., and Lipowsky H.H. Inflammation and ischemia induced shedding of the venular glycocalyx. Am J Physiol Heart Circ Physiol 286 (2004) H1672-H1680
6. Wuillemin W.A., te Velthuis H., Lubbers Y.T., de Ruig C.P., Eldering E., and Hack C.E. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 159 (1997) 1953-1960
7. Laumonier T., Walpen A., Maurus C., Mohacsi P.J., Matozan K., Korchagina E., Bovin N., Vanhove B., Seebach J.D., and Rieben R. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement- and NK cell-mediated cytotoxicity against porcine cells. Transplantation 76 (2003) 838-843
8. Zeerleder S., Mauron T., Lammle B., and Wuillemin W.A. Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res 105 (2002) 441-446
9. Banz Y., Hess O.M., Robson S.C., Mettler D., Meier P., Haeberli A., Csizmadia E., Korchagina E.Y., Bovin N.V., and Rieben R. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. Eur Heart J 26 (2005) 2334-2343
10. Daha M.R., and Van Es L.A. Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages. Immunology 43 (1981) 513-518
11. Shaw S.G., Schmid M., and Casty A. Critical factors in the radioimmunoassay of endothelin-1, endothelin-3, and big endothelin-1 in human plasma. Anal Biochem 278 (2000) 143-149
12. Creswell L.L., Alexander Jr. J.C., Ferguson Jr. T.B., Lisbon A., and Fleisher L.A. Intraoperative interventions: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 128 (2005) 28S-35S
13. Gaudino M., Andreotti F., Zamparelli R., Di Castelnuovo A., Nasso G., Burzotta F., Iacoviello L., Donati M.B., Schiavello R., Maseri A., and Possati G. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?. Circulation 108 Suppl. 1 (2003) II195-II199
14. Royston D., Minty B.D., Higenbottam T.W., Wallwork J., and Jones G.J. The effect of surgery with cardiopulmonary bypass on alveolar-capillary barrier function in human beings. Ann Thorac Surg 40 (1985) 139-143
15. Komai H., Naito Y., and Okamura Y. Dextran sulfate as a leukocyte-endothelium adhesion molecule inhibitor of lung injury in pediatric open-heart surgery. Perfusion 20 (2005) 77-82
16. Immer F.F., Pirovino C., Gygax E., Englberger L., Tevaearai H., and Carrel T.P. Minimal versus conventional cardiopulmonary bypass: assessment of intraoperative myocardial damage in coronary bypass surgery. Eur J Cardiothorac Surg 28 (2005) 701-704
17. Parolari A., Colli S., Mussoni L., Eligini S., Naliato M., Wang X., Gandini S., Tremoli E., Biglioli P., and Alamanni F. Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 336-343
18. Ostrovsky L., Woodman R.C., Payne D., Teoh D., and Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96 (1997) 2302-2310
19. Lazar H.L., Bao Y., Gaudiani J., Rivers S., and Marsh H. Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 100 (1999) 1438-1442
20. Jansen P.G., te Velthuis H., Huybregts R.A., Paulus R., Bulder E.R., van der Spoel H.I., Bezemer P.D., Slaats E.H., Eijsman L., and Wildevuur C.R. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 110 (1995) 829-834
21. Marin V., Montero-Julian F.A., Gres S., Boulay V., Bongrand P., Farnarier C., and Kaplanski G. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 167 (2001) 3435-3442
22. Walker C.A., Baicu S.C., Goldberg A.T., Widener C.E., Fary D.J., Almany D.K., Ergul A., Crawford Jr. F.A., and Spinale F.G. Temporal endothelin dynamics of the myocardial interstitium and systemic circulation in cardiopulmonary bypass. J Thorac Cardiovasc Surg 120 (2000) 864-871
23. Liakopoulos O.J., Schmitto J.D., Kazmaier S., Brauer A., Quintel M., Schoendube F.A., and Dorge H. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg 84 (2007) 110-118 discussion 118-9
24. Chaney M.A., Durazo-Arvizu R.A., Nikolov M.P., Blakeman B.P., and Bakhos M. Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. J Thorac Cardiovasc Surg 121 (2001) 561-569
25. Fujishima M., Omae T., Tanaka K., Iino K., Matsuo O., and Mihara H. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 37 (1986) 487-498